Author's Response to "A Letter in Support of Real-World RECIST"

Adv Ther. 2020 Apr;37(4):1691-1693. doi: 10.1007/s12325-020-01246-9. Epub 2020 Feb 13.

Abstract

No abstract available

Keywords: Carcinoma; Endpoints; Immunotherapy; Non-small-cell lung; PD-1; PD-L1; Real-world evidence.

Publication types

  • Letter